Ai X et al. A phase 2 dose expansion study of ZG006, a trispecific T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with advanced small cell lung cancer. ASCO 2025;Abstract 8007.
Aix SP et al. Safety and efficacy of lurbinectedin plus atezolizumab as second-line treatment for advanced small-cell lung cancer: Results of the 2SMALL phase 1/2 study (NCT04253145). ASCO 2025;Abstract 8013.
Besse B et al. A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator's choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial). ASCO 2023;Abstract TPS8613.
Cheng Y et al. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N Engl J Med 2024;391(14):1313-27. Abstract
Grønberg BH et al. High-dose versus standard-dose twice-daily thoracic radiotherapy in limited-stage SCLC: Final survival data, long-term toxicity, and relapse patterns in a randomized, open-label, phase II trial. J Thorac Onc 2025;20(7)969-82. Abstract
Grønberg BH et al. Randomized phase II trial investigating whether atezolizumab after chemoradiotherapy (CRT) prolongs survival in limited stage (LS) small cell lung cancer (SCLC). ASCO 2025;Abstract LBA8005.
Hayashi H et al. IDeate-Lung01: A phase 2 trial of ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer. JSMO 2025;Abstract O12-4.
Hayashi H et al. IDeate-Lung02: Phase 3 study of ifinatamab deruxtecan (I-DXd) in relapsed small cell lung cancer. JSMO 2025;Abstract P93-5.
Hayashi H et al. Ifinatamab deruxtecan (I-DXd) + atezolizumab ± carboplatin as first line therapy for extensive-stage small cell lung cancer. JSMO2025;Abstract P93-6.
Meador CB et al. Breaking new ground in small cell lung cancer: BiTE, TriTE and chemoimmunotherapy. ASCO 2025;Discussant.
Mountzios G et al. Tarlatamab in small-cell lung cancer after platinum-based chemotherapy. N Engl J Med 2025;[Online ahead of print]. Abstract
Paz-Ares L et al. Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): A randomised, multicentre, open-label, phase 3 trial. Lancet 2025;405(10495):2129-43. Abstract
Paz-Ares LG et al. Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial. ASCO 2025;Abstract 8006.
Rudin CM et al. Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis of ph3 DeLLphi-304. ASCO 2025;Abstract LBA8008.
Spigel DR et al. ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC). ASCO 2024;Abstract LBA5.